Search
                    Carboplatin Treatment Options in Texas
A collection of 635 research studies where Carboplatin is the interventional treatment. These studies are located in the Texas, United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
            613 - 624 of 635
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
                                
            
            
        Terminated
                            
            
                Primary Objectives:
1. To test whether the addition of chemotherapy to radiotherapy improves the progression-free survival for patients with stage I, II and IIIa malignant mixed mesodermal tumor (MMMT) of the uterus.
2. To determine the acute and late toxicity profiles associated with this treatment regimen.
3. To describe the effect of this treatment regimen on the patient's quality of life.             
        
        
    Gender:
                FEMALE
            Ages:
                All
            Trial Updated:
                09/13/2011
            
            Locations: UT MD Anderson Cancer Center, Houston, Texas         
        
        
            Conditions: Uterine Neoplasms
        
            
        
    
                
                                    A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
                                
            
            
        Completed
                            
            
                The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/13/2011
            
            Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas  +3 locations         
        
        
            Conditions: Non-Small Cell Lung Cancer
        
            
        
    
                
                                    A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
                                
            
            
        Completed
                            
            
                This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.             
        
        
    Gender:
                ALL
            Ages:
                Between 1 year and 21 years
            Trial Updated:
                04/07/2011
            
            Locations: Local Institution, Houston, Texas         
        
        
            Conditions: Neoplasms
        
            
        
    
                
                                    Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
                                
            
            
        Unknown
                            
            
                This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/24/2011
            
            Locations: University of Texas MD Anderson Cancer Center, Houston, Texas         
        
        
            Conditions: Glioblastoma Multiforme
        
            
        
    
                
                                    An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
                                
            
            
        Completed
                            
            
                This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. Patients with disease after induction therapy will crossover to receive single agent therapy.             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                02/28/2011
            
            Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas  +1 locations         
        
        
            Conditions: Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
        
            
        
    
                
                                    Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
                                
            
            
        Unknown
                            
            
                RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment.
PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                02/26/2011
            
            Locations: Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas  +1 locations         
        
        
            Conditions: Lung Cancer
        
            
        
    
                
                                    Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with peripheral stem cell transplantation in treating children who have central nervous system cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and below
            Trial Updated:
                02/25/2011
            
            Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas         
        
        
            Conditions: Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
        
            
        
    
                
                                    A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
                                
            
            
        Completed
                            
            
                N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/27/2010
            
            Locations: Texas Oncology, PA, Dallas, Texas  +1 locations         
        
        
            Conditions: Neoplasms
        
            
        
    
                
                                    N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell or bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
PURPOSE: This phase I trial is studying the side effects and best dose of combination chemotherapy whe...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 1 year and 21 years
            Trial Updated:
                10/14/2010
            
            Locations: Texas Children's Cancer Center, Houston, Texas         
        
        
            Conditions: Neuroblastoma
        
            
        
    
                
                                    Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
                                
            
            
        Terminated
                            
            
                The purpose of this study is to help answer:
* Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical removal and chemotherapy), and to determine how long this will last
* Whether pemetrexed, gemcitabine and/or carboplatin can help patients with relapsed lung cancer live longer             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/09/2010
            
            Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas         
        
        
            Conditions: Lung Neoplasms
        
            
        
    
                
                                    A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
                                
            
            
        Completed
                            
            
                The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/14/2010
            
            Locations: Pfizer Investigational Site, Burleson, Texas  +4 locations         
        
        
            Conditions: Non-small Cell Lung Cancer
        
            
        
    
                
                                    Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
                                
            
            
        Completed
                            
            
                The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/08/2010
            
            Locations: ImClone Investigational Site, Houston, Texas  +1 locations         
        
        
            Conditions: Non-small Cell Lung Cancer
        
            
        
    613 - 624 of 635
            